Technetium-99m production issues in the United Kingdom

Area of Science:

• Nuclear Medicine
• Radiopharmaceutical Chemistry
• Medical Imaging

Background:

• Early nuclear medicine utilized Iodine-131 for thyroid imaging, but limitations in energy and emission characteristics led to suboptimal image quality and long acquisition times.
• Technetium-99m (Tc-99m) emerged as a superior radionuclide due to its favorable 140 keV gamma emission and 6-hour half-life, enabling imaging of diverse organs.
• Tc-99m is eluted from Molybdenum-99 (Mo-99) using generators, with Mo-99 sourced from high-flux research reactors and supplied weekly by radiopharmaceutical companies.

Purpose of the Study:

• To highlight the historical development and advantages of Technetium-99m in nuclear medicine.
• To explain the critical dependence of Tc-99m supply on Molybdenum-99 production.
• To address the significant global shortages of Mo-99 experienced since 2007 and their impact on nuclear medicine.

Main Methods:

• Review of the evolution of radionuclides in nuclear medicine, from Iodine-131 to Technetium-99m.
• Explanation of the Mo-99/Tc-99m generator system and its supply chain logistics.
• Analysis of the causes and consequences of Molybdenum-99 shortages linked to research reactor downtime and aging infrastructure.

Main Results:

• Technetium-99m offers significant improvements over Iodine-131 for medical imaging due to its physical properties.
• The global supply of Tc-99m is vulnerable to disruptions in Mo-99 production, primarily from aging research reactors.
• Widespread Mo-99 shortages occurred around 2007 and continue to be a risk due to the age of primary production reactors and lack of governmental foresight.

Conclusions:

• The reliability of nuclear medicine diagnostics is directly threatened by the aging infrastructure of Mo-99 producing reactors.
• Urgent need for governmental investment in new reactor technologies and robust supply chain strategies to ensure future availability of Mo-99 and Tc-99m.
• The historical reliance on a few aging reactors for Mo-99 production presents a critical vulnerability for global nuclear medicine.